Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2025-01-03T12:49:44.405Z Has data issue: false hasContentIssue false
  • English
  • Français

Ospolot—A Clinical Trial of a New Anticonvulsant

Published online by Cambridge University Press:  29 January 2018

A. W. Griffiths  and
P. E. Sylvester
A. W. Griffiths
Affiliation:
St. Lawrence's Hospital, Caterham, Surrey
P. E. Sylvester
Affiliation:
St. Lawrence's Hospital, Caterham, Surrey
Get access Rights & Permissions [Opens in a new window]

Extract

Ospolot is tetrahydro-2-p-sulphamoylphenyl-1, 2 thiazine 1, 1-dioxide, with a structural formula:

Type
Research Article
Information
The British Journal of Psychiatry , Volume 110 , Issue 465 , March 1964 , pp. 261 - 266
Copyright
Copyright © Royal College of Psychiatrists, 1964 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Engelmeier, M. P. (1960). “The clinical trial of anti-epileptic drugs, with special consideration of Ospolot.” Dtsch. med. Wsckr., 85, 2207.Google Scholar
Flügel, F. (1960). “The position of the butansultam derivative Ospolot in the treatment of cerebral convulsive diseases.” Ibid., 85, 2199.Google Scholar
Friebel, H., and Sommers, S. (1960). “Some aspects of the pharmacology of N-aryl-sultam compounds.” Ibid., 85, 2192.Google Scholar
Raffauf, H. J. (1960). “Treatment of cerebral convulsive diseases with Ospolot.” Ibid., 85, 2203.Google Scholar
Wirth, W. et al. (1960). “Some aspects of the pharmacology of Ospolot (N-4′-sulphamyl-phenyl-butansultam-1-4).” Ibid., 85, 2195.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.